Table 2.
Comparison Between Sitagliptin and Voglibose in Effects on Clinical and Biochemical Parameters and Endothelial Function
| Sitagliptin | Voglibose | P Value | |||
|---|---|---|---|---|---|
| Mean±SD | % Change From Baseline | Mean±SD | %Change From Baseline | ||
| Body weight, kg | 86.2±19.1 | −5.0 | 81.6±23.1 | 1.0 | 0.228 |
| Systolic blood pressure, mm Hg | 131±10 | 0.9 | 128±13 | −0.9 | 0.475 |
| Diastolic blood pressure, mm Hg | 87±9 | 2.1 | 82±11 | −3.3 | 0.093 |
| Biochemical parameters | |||||
| Fasting blood glucose, mg/dL | 137±43 | −5.5 | 145±43 | 1.4 | 0.204 |
| Hemoglobin A1c, % | 6.73±1.5 | −5.0 | 6.77±1.38 | −4.5 | 0.845 |
| Glycated albumin, % | 16.7±5.5 | −7.8 | 17.4±5.0 | −2.8 | 0.087 |
| Immunoreactive insulin, μU/mL | 10.3±9.0 | 8.4 | 11.4±12.5 | −4.1 | 0.413 |
| Total cholesterol, mg/dL | 200±36 | −0.7 | 213±37 | 6.8 | 0.136 |
| LDL cholesterol, mg/dL | 123±30 | 0.4 | 136±28 | 10.7 | 0.193 |
| HDL cholesterol, mg/dL | 56.5±13.6 | 9.2 | 53.0±10.3 | 2.3 | 0.322 |
| Triglycerides, mg/dL | 141 (102 to 254) | 2.9 | 136 (104 to 251) | −0.7 | 0.927 |
| Endothelial function | |||||
| Basal diameter before FMD, mm | 4.83±0.60 | −0.9 | 4.72±0.57 | −3.2 | 0.272 |
| Peak diameter after FMD, mm | 4.94±0.62 | −2.9 | 4.96±0.57 | −2.6 | 0.843 |
| FMD, % | 2.13±3.63 | −51.1 | 5.07±3.49 | 16.4 | 0.038 |
| Basal diameter before NMD, mm | 4.84±0.60 | −0.9 | 4.76±0.57 | −2.7 | 0.394 |
| Peak diameter after NMD, mm | 5.59±0.63 | −2.0 | 5.58±0.63 | −2.1 | 0.977 |
| NMD, % | 16.2±6.6 | −5.8 | 18.0±6.3 | 4.8 | 0.394 |
SD indicates standard deviation; LDL, low‐density lipoprotein; HDL, high‐density lipoprotein; FMD, flow‐mediated vasodilatation; NMD, nitroglycerin‐mediated vasodilatation. Values are mean±SD except for triglycerides (median [interquartile range]). P value of sitagliptin vs alogliptin treatment.